These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19784846)

  • 1. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer.
    Zimmers TA; Gutierrez JC; Koniaris LG
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):571-6. PubMed ID: 19784846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac.
    Wang X; Kingsley PJ; Marnett LJ; Eling TE
    Cancer Prev Res (Phila); 2011 Jan; 4(1):150-60. PubMed ID: 21205743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice.
    Greenspan EJ; Nichols FC; Rosenberg DW
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1187-97. PubMed ID: 20716632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.
    Itano O; Yang K; Fan K; Kurihara N; Shinozaki H; Abe S; Jin B; Gravaghi C; Edelmann W; Augenlicht L; Kopelovich L; Kucherlapati R; Lamprecht S; Lipkin M
    Carcinogenesis; 2009 Nov; 30(11):1923-6. PubMed ID: 19755659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice.
    McEntee MF; Chiu CH; Whelan J
    Carcinogenesis; 1999 Apr; 20(4):635-40. PubMed ID: 10223192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression.
    Ritland SR; Gendler SJ
    Carcinogenesis; 1999 Jan; 20(1):51-8. PubMed ID: 9934849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
    Alberts DS; Hixson L; Ahnen D; Bogert C; Einspahr J; Paranka N; Brendel K; Gross PH; Pamukcu R; Burt RW
    J Cell Biochem Suppl; 1995; 22():18-23. PubMed ID: 8538196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.
    Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM
    Carcinogenesis; 1998 Jan; 19(1):87-91. PubMed ID: 9472698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon.
    Mladenova D; Daniel JJ; Dahlstrom JE; Bean E; Gupta R; Pickford R; Currey N; Musgrove EA; Kohonen-Corish MR
    Gut; 2011 Mar; 60(3):350-60. PubMed ID: 20980345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs.
    Leibowitz B; Qiu W; Buchanan ME; Zou F; Vernon P; Moyer MP; Yin XM; Schoen RE; Yu J; Zhang L
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16520-5. PubMed ID: 25368155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer.
    Wechter WJ; Kantoci D; Murray ED; Quiggle DD; Leipold DD; Gibson KM; McCracken JD
    Cancer Res; 1997 Oct; 57(19):4316-24. PubMed ID: 9331093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC.
    Faux MC; Weinstock J; Gogos S; Prato E; Azimpour AI; O'Keefe R; Cathcart-King Y; Garnham AL; Ernst M; Preaudet A; Christie M; Putoczki TL; Buchert M; Burgess AW
    Cancer Res Commun; 2022 Feb; 2(2):66-77. PubMed ID: 36860494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention.
    Fischer JM; Schepers AG; Clevers H; Shibata D; Liskay RM
    Carcinogenesis; 2014 Jan; 35(1):237-46. PubMed ID: 23996931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations.
    Yang K; Fan K; Kurihara N; Shinozaki H; Rigas B; Augenlicht L; Kopelovich L; Edelmann W; Kucherlapati R; Lipkin M
    Carcinogenesis; 2003 Mar; 24(3):605-11. PubMed ID: 12663524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
    DuBois RN; Giardiello FM; Smalley WE
    Gastroenterol Clin North Am; 1996 Dec; 25(4):773-91. PubMed ID: 8960892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
    Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
    Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.
    Chiu CH; McEntee MF; Whelan J
    Cancer Res; 1997 Oct; 57(19):4267-73. PubMed ID: 9331087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac.
    Mahmoud NN; Bilinski RT; Churchill MR; Edelmann W; Kucherlapati R; Bertagnolli MM
    Cancer Res; 1999 Jan; 59(2):353-9. PubMed ID: 9927046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
    Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.